Literature DB >> 19821781

The role of labile iron in kidney disease and treatment with chelation.

Sudhir V Shah1, Mohan M Rajapurkar.   

Abstract

There are two major forms of kidney disease: acute renal failure [also referred to as acute kidney injury (AKI)] and chronic kidney disease (CKD). Acute renal failure is an abrupt loss of kidney function within 48 h, whereas CKD is a loss of kidney function greater than 3 months. There is a large amount of experimental evidence for an increase of labile iron in a wide variety of models of kidney disease. Additionally, iron chelators provide protection, indicating an important role of labile iron in these diseases. These observations suggest that iron chelators may provide a new modality of prevention and treatment of kidney disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19821781     DOI: 10.3109/03630260903212233

Source DB:  PubMed          Journal:  Hemoglobin        ISSN: 0363-0269            Impact factor:   0.849


  9 in total

1.  The oral iron chelator deferiprone protects against iron overload-induced retinal degeneration.

Authors:  Majda Hadziahmetovic; Ying Song; Natalie Wolkow; Jared Iacovelli; Steven Grieco; Jennifer Lee; Arkady Lyubarsky; Domenico Pratico; John Connelly; Michael Spino; Z Leah Harris; Joshua L Dunaief
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-16       Impact factor: 4.799

Review 2.  Role of iron in ischemia-induced neurodegeneration: mechanisms and insights.

Authors:  Gillipsie Minhas; Shweta Modgil; Akshay Anand
Journal:  Metab Brain Dis       Date:  2014-03-11       Impact factor: 3.584

Review 3.  Iron supplementation to treat anemia in patients with chronic kidney disease.

Authors:  Anatole Besarab; Daniel W Coyne
Journal:  Nat Rev Nephrol       Date:  2010-10-19       Impact factor: 28.314

4.  Redox nanomedicine ameliorates chronic kidney disease (CKD) by mitochondrial reconditioning in mice.

Authors:  Aniruddha Adhikari; Susmita Mondal; Tanima Chatterjee; Monojit Das; Pritam Biswas; Ria Ghosh; Soumendra Darbar; Hussain Alessa; Jalal T Althakafy; Ali Sayqal; Saleh A Ahmed; Anjan Kumar Das; Maitree Bhattacharyya; Samir Kumar Pal
Journal:  Commun Biol       Date:  2021-08-26

5.  Iron chelator alleviates tubulointerstitial fibrosis in diabetic nephropathy rats by inhibiting the expression of tenascinC and other correlation factors.

Authors:  Chunbo Zou; Rujuan Xie; Yushi Bao; Xiaogang Liu; Manshu Sui; Suhong M; Shuang Li; Huiqing Yin
Journal:  Endocrine       Date:  2013-03-07       Impact factor: 3.633

6.  Systemic administration of the iron chelator deferiprone protects against light-induced photoreceptor degeneration in the mouse retina.

Authors:  Delu Song; Ying Song; Majda Hadziahmetovic; Yong Zhong; Joshua L Dunaief
Journal:  Free Radic Biol Med       Date:  2012-05-01       Impact factor: 7.376

7.  Epigenomic regulation by labile iron.

Authors:  Vladimir Camarena; Tyler C Huff; Gaofeng Wang
Journal:  Free Radic Biol Med       Date:  2021-01-22       Impact factor: 8.101

8.  BCc1 Nanomedicine Therapeutic Effects in Streptozotocin and High-Fat Diet Induced Diabetic Kidney Disease.

Authors:  Saideh Fakharzadeh; Hassan Argani; Simin Dadashzadeh; Somayeh Kalanaky; Peyman Mohammadi Torbati; Mohammad Hassan Nazaran; Abbas Basiri
Journal:  Diabetes Metab Syndr Obes       Date:  2020-04-17       Impact factor: 3.168

9.  Regulation of divalent metal transporter-1 by serine phosphorylation.

Authors:  Young Ah Seo; Ruvin Kumara; Herbert Wetli; Marianne Wessling-Resnick
Journal:  Biochem J       Date:  2016-09-28       Impact factor: 3.857

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.